Добірка наукової літератури з теми "Continuous pharmaceutical manufacturing"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Continuous pharmaceutical manufacturing".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Continuous pharmaceutical manufacturing"
Korhonen, Ossi. "Continuous Pharmaceutical Manufacturing." Pharmaceutics 12, no. 10 (September 23, 2020): 910. http://dx.doi.org/10.3390/pharmaceutics12100910.
Повний текст джерелаBurcham, Christopher L., Alastair J. Florence, and Martin D. Johnson. "Continuous Manufacturing in Pharmaceutical Process Development and Manufacturing." Annual Review of Chemical and Biomolecular Engineering 9, no. 1 (June 7, 2018): 253–81. http://dx.doi.org/10.1146/annurev-chembioeng-060817-084355.
Повний текст джерелаHock, Sia Chong, Teh Kee Siang, and Chan Lai Wah. "Continuous manufacturing versus batch manufacturing: benefits, opportunities and challenges for manufacturers and regulators." Generics and Biosimilars Initiative Journal 10, no. 1 (March 15, 2021): 44–56. http://dx.doi.org/10.5639/gabij.2021.1001.004.
Повний текст джерелаTAHARA, Kohei. "Spherical Crystallization for Pharmaceutical Continuous Manufacturing System." Hosokawa Powder Technology Foundation ANNUAL REPORT 25 (2017): 75–78. http://dx.doi.org/10.14356/hptf.15111.
Повний текст джерелаMay, Scott A. "Flow chemistry, continuous processing, and continuous manufacturing: A pharmaceutical perspective." Journal of Flow Chemistry 7, no. 3–4 (September 2017): 137–45. http://dx.doi.org/10.1556/1846.2017.00029.
Повний текст джерелаDesai, Parind Mahendrakumar, Griet Van Vaerenbergh, Jim Holman, Celine Valeria Liew, and Paul Wan Sia Heng. "Continuous manufacturing: the future in pharmaceutical solid dosage form manufacturing." Pharmaceutical Bioprocessing 3, no. 5 (September 2015): 357–60. http://dx.doi.org/10.4155/pbp.15.19.
Повний текст джерелаMyerson, Allan S., Markus Krumme, Moheb Nasr, Hayden Thomas, and Richard D. Braatz. "Control Systems Engineering in Continuous Pharmaceutical Manufacturing May 20–21, 2014 Continuous Manufacturing Symposium." Journal of Pharmaceutical Sciences 104, no. 3 (March 2015): 832–39. http://dx.doi.org/10.1002/jps.24311.
Повний текст джерелаWahlich, John. "Review: Continuous Manufacturing of Small Molecule Solid Oral Dosage Forms." Pharmaceutics 13, no. 8 (August 22, 2021): 1311. http://dx.doi.org/10.3390/pharmaceutics13081311.
Повний текст джерелаLee, Sau L., Thomas F. O’Connor, Xiaochuan Yang, Celia N. Cruz, Sharmista Chatterjee, Rapti D. Madurawe, Christine M. V. Moore, Lawrence X. Yu, and Janet Woodcock. "Modernizing Pharmaceutical Manufacturing: from Batch to Continuous Production." Journal of Pharmaceutical Innovation 10, no. 3 (March 19, 2015): 191–99. http://dx.doi.org/10.1007/s12247-015-9215-8.
Повний текст джерелаRehrl, Jakob, Julia Kruisz, Stephan Sacher, Johannes Khinast, and Martin Horn. "Optimized continuous pharmaceutical manufacturing via model-predictive control." International Journal of Pharmaceutics 510, no. 1 (August 2016): 100–115. http://dx.doi.org/10.1016/j.ijpharm.2016.06.024.
Повний текст джерелаДисертації з теми "Continuous pharmaceutical manufacturing"
Abel, Matthew J. "Process systems engineering of continuous pharmaceutical manufacturing." Thesis, Massachusetts Institute of Technology, 2009. http://hdl.handle.net/1721.1/58446.
Повний текст джерелаCataloged from PDF version of thesis.
Includes bibliographical references (p. 290-299).
Continuous manufacturing offers a number of operational and financial benefits to pharmaceutical companies. This research examines the critical blending step for continuous pharmaceutical manufacturing and the characteristics of continuous downstream pharmaceutical manufacturing systems. Discrete element method (DEM) simulations were used to develop novel insights into the mechanism of mixing for continuous blending of cohesive pharmaceutical powders and to examine the effects of particle properties, blender design and operating conditions on blend homogeneity. To place continuous blending into the context of pharmaceutical manufacturing, the scope of the analysis was expanded to process system models of continuous downstream pharmaceutical manufacturing. DEM simulations were used to study the mechanisms of mixing in the continuous blending of pharmaceutical powders. Diffusive mixing from the avalanching particles appears to be the dominant mechanism of mixing in both the axial and radial direction for the double helical ribbon blender. This result can guide the development of future continuous pharmaceutical powder blenders by optimizing the mixing elements to increase the amount of particles transported to a position where they can avalanche/flow and diffusively mix. A range of particle properties, blender designs and operating conditions were examined for their effects on flow behavior and blend homogeneity. Three particle properties were examined: particle size, polydispersity and cohesive force.
(cont.) Particle size was observed to be positively correlated to both flow rates and blend homogeneity. Polydispersity had no effect on flow rate and was negatively correlated to homogeneity. Cohesive force was negatively correlated to flow rate and had little to no effect on homogeneity. Two modifications of blender design were analyzed: changes in blender size and changes in shaft design. Blender size was observed to be positively correlated to flow rate and negatively correlated to homogeneity. The paddle shaft designs created a more homogeneous powder blend than the double helical ribbon shaft. Two operating parameters were also studied: rotation rate and fill fraction. Rotation rate was positively correlated to both flow rate and homogeneity. Fill fraction had the interesting result of being positively correlated to the absolute flow rate, but negatively correlated to the fill mass normalized flow rate. In addition, fill fraction has a clear negative correlation to homogeneity above fill fractions of 0.55, but is inconsistent for fill fractions lower than this. This research on particle properties, blender designs and operating conditions will help to guide the operation of continuous pharmaceutical blenders and the design of continuous pharmaceutical manufacturing systems. Process simulations comparing model batch and continuous downstream pharmaceutical manufacturing systems have quantified some of the potential size, cost and performance benefits of continuous processes. The models showed significant reductions in process equipment sizes for continuous manufacturing particularly in the blending step.
(cont.) This reduction in equipment size translates to capital cost (CAPEX) savings for both the continuous process equipment and manufacturing facilities. The steady state operation of continuous processing also reduces the labor requirements and gives the continuous processes an operating cost (OPEX) advantage over batch processes. This research has contributed to the understanding of continuous pharmaceutical powder blending and quantified some of the benefits of continuous downstream pharmaceutical manufacturing. This work is being continued by the Novartis-MIT Center for Continuous Manufacturing whose work is providing the foundation for future industrial scale pharmaceutical continuous manufacturing systems.
by Matthew J. Abel.
Ph.D.
Bell, Erin R. "Melt extrusion and continuous manufacturing of pharmaceutical materials." Thesis, Massachusetts Institute of Technology, 2011. http://hdl.handle.net/1721.1/65755.
Повний текст джерелаCataloged from PDF version of thesis.
Includes bibliographical references.
Melt extrusion is an alternative processing technique that operates continuously, reduces the total number of unit operations, allows for incorporation of difficult-to-process drug substances, and has the potential to achieve tablets of better quality and consistency compared to traditional methods. Thus, our goal was to evaluate melt extrusion as a viable processing alternative and expand our scientific knowledge such that we gain predictive capabilities of tablet characteristics, i.e., quality by design. This new knowledge will aid future process design thereby helping to reduce time and costs associated with pharmaceutical solid dosage form production. The residence time distribution for melt extrusion has been characterized using a single parameter model. When combined with assumed first-order reaction rate kinetics and an Arrhenius reaction rate constant, the model can accurately predict the amount of drug product lost to temperature driven degradation. The model prediction agreed well with experimentally determined fractional conversion. The physical stability of amorphous Molecule A was characterized using enthalpy of relaxation measurements. Molecular level rearrangements are the source of physical instability for the fragile glass forming Molecule A. The instability can be modified by introducing a second component, which contributes to the overall enthalpy change. Coating amorphous Molecule A tablets with a polyvinyl alcohol based coating material reduces moisture uptake during storage. The coating material preferentially uptakes water from the atmosphere, restricting moisture from entering the tablet core and causing premature dissolution or degradation. The dissolution behavior of Molecule A tablets can be tailored with the addition of water soluble materials. Dissolution rate constants for Molecule A tablets have been calculated for different formulations and can be used as a resource when designing new solid dosage forms with desired dissolution characteristics. A novel 100% Molecule A melt extrusion process has been created, reducing the number of overall unit operations and eliminating troublesome blending inconsistencies. An additional formulation that maintains the crystallinity of Molecule A by processing with polyethylene glycol below Molecule A's melting temperature is physically and chemically stable and ready for implementation in a continuous production line. The mixing achieved within the extruder for this formulation is sufficient to eliminate a pre-mixing unit operation.
by Erin R. Bell.
Ph.D.
Tan, Li Ph D. Massachusetts Institute of Technology. "Heterogeneous nucleation of active pharmaceutical ingredients on polymers : applications in continuous pharmaceutical manufacturing." Thesis, Massachusetts Institute of Technology, 2015. http://hdl.handle.net/1721.1/101511.
Повний текст джерелаCataloged from PDF version of thesis.
Includes bibliographical references (pages 92-105).
In this thesis work, we aimed to explore crystallization processes for small molecule API compounds based on engineered polymer surfaces that could be used in continuous manufacturing. First, we identified a library of polymers that can be used and selected PVA as the model polymer based on its solution and film properties. We also illustrated a rational approach for designing and fabricating PVA film surfaces for increasing heterogeneous nucleation rate of different compounds and enable polymorph selection. The design philosophy was to select prevalent angles between major faces of crystals according to a selection of compounds, and to create substrate surfaces with indentations that include these angles. Nucleation induction time trends showed that heterogeneous nucleation rates were accelerated by at least an order of magnitude in the presence of PVA due to the favorable interactions between the model compounds and the polymer. Nucleation rates were further increased for patterned substrates with matching geometries. Surface indentations with non-matching angles resulted in faster nucleation rates than flat films but slower than matching geometries because they only increased the effective area of the films and their roughness. X-ray diffraction was used to reveal faces that preferentially interacted with the PVA side chains and to deduce possible arrangement of solute molecules at the corners of the indentations. Combining X-ray data and morphology of the crystal product, we suggest that matching geometries on the substrate enhanced nucleation of compounds. In addition to enhancing nucleation rate, polymorph selection was possible in the presence of the polymer substrate to yield a higher percentage of thermodynamically stable gamma indomethacin. Offline Raman experiments and in-line morphology determination confirmed that polymorph control of the final crystal product via kinetic control of the nucleation process was viable. For the aspirin system, the 85 degree angle lead to the highest rate of nucleation; for the polymorphic indomethacin system, XRPD results showed that gamma form preferentially formed on the PVA films with 65 and 80 degree angles leading to the largest reduction in nucleation induction time. Kinetic Monte Carlo simulation showed that a crystallizer incorporating both nucleation and crystal growth in the absence of active mass transfer would have too small a throughput and too large a footprint to be useful. The main reasons were long average nucleation induction times and slow crystal growth in the absence of convection. A set of batch desupersaturation experiments showed that mass transfer limited growth dominate the crystal growth kinetics at low supersaturations when nucleation events were suppressed. An increase in the bulk fluid velocity increased the effective growth kinetics in the system when mass transfer kinetics dominated. Steady state modeling based on the first principle approach was performed using a combination of Navier Stokes Equations and diffusion-convection mass transport equations. The modeling result demonstrated that for mass transfer from a moving fluid to a stationary surface, a thin momentum and concentration boundary layer existed at the leading edge, which resulted in much higher local mass transfer rates. In the absence of momentum boundary layers, mass transfer could only occur via diffusion, which resulted in slow growth kinetics. The first principle model was used to derive dimensionless number correlations for the continuous crystallizer.
by Li Tan.
Ph. D.
Barcena, Jose R. (Jose Roberto). "Materials properties of pharmaceutical formulations for thin-film-tablet continuous manufacturing." Thesis, Massachusetts Institute of Technology, 2012. http://hdl.handle.net/1721.1/76120.
Повний текст джерелаPage 43 blank. Cataloged from PDF version of thesis.
Includes bibliographical references (p. 41-42).
The development of manufacturing tablets in a continuous way has been possible greatly to the fabrication of polymer based thin-films. It is estimated that the pharmaceutical industry loses as much as a 25% on revenues based on the currently employed batch manufacturing method. Here we studied a continuous way of manufacturing tablets based on API/based polymer formulations that are cast and subsequently rolled into a tablet. Selections of two active pharmaceutical ingredients (SPP-100 and Acetaminophen) were studied into how well it forms mechanical robust, chemical and physical compatible HPMC polymer based films. As well, HPMC polymer based films with no drug loading were compared to measure out the dispersion of the drug on the film. Physiochemical studies were performed by DSC, XRD, FT-IR, and SEM. Moisture content was measured out by Karl Fischer Titration and mechanical properties such as tensile strength were measured for all API/HPMC and placebo films. It was found that the mechanical and physiochemical properties of SPP-100/HPMC films were regarded as the most promising thin film tablet candidate and it is further being tested for other mechanical properties such as bonding, friction, and compression.
by Jose R. Barcena.
S.B.
Slaughter, Ryan (Ryan R. ). "The development of a thin-film rollforming process for pharmaceutical continuous manufacturing." Thesis, Massachusetts Institute of Technology, 2013. http://hdl.handle.net/1721.1/81136.
Повний текст джерелаCataloged from PDF version of thesis.
Includes bibliographical references (p. 51-53).
In this thesis, a continuous rollforming process for the folding of thin-films was proposed and studied as a key step in the continuous manufacturing of pharmaceutical tablets. HPMC and PEG based polymeric thin-films were considered for this application. An experimental apparatus was designed and developed to test the folding of thin-films. The experimental apparatus was designed in a modular fashion to facilitate testing of various process parameters. Analysis was carried out for the folding operations, based on which two folding strategies were proposed - (i) without scoring and (ii) with scoring. The first strategy relies on elastic deformation of the thin-films, whereas the later depends on localized, plastic deformation caused by the scoring geometry. From the experiments on folding we identified three regimes of process operation namely: insufficient scoring, appropriate scoring, and excessive scoring. The implications of different levels of scoring were observed and understood carefully for the scoring and folding operation. Practical guidelines were developed for carrying out folding successfully and the scope of future work was discussed.
by Ryan Slaughter.
S.M.
Foguth, Lucas Charles. "Integration of quality-by-design into control systems design for continuous pharmaceutical manufacturing." Thesis, Massachusetts Institute of Technology, 2016. http://hdl.handle.net/1721.1/104204.
Повний текст джерелаCataloged from PDF version of thesis.
Includes bibliographical references (pages 121-126).
In the pharmaceutical industry there has recently been much interest in design spaces: sets of critical process parameters (CPPs) which guarantee that critical quality attributes (CQAs) of a manufacturing process are within specifications. For continuous pharmaceutical processes, design spaces are usually calculated by assuming steady state operation and approximating the mapping between CPPs and CQAs using a Taylor series. The full design space can then be calculated using a plantwide approach or a unit-by-unit approach. Common inner approximations of the design space (e.g. hyper-rectangles) can result in significant conservatism, especially when a unit-by-unit approach is employed. Because control loops tend to have a linearizing effect on processes, design spaces for closed-loop processes can often be calculated using low-order Taylor series approximations, resulting in simpler expressions for the full design space (e.g. polytopes). Control loops also tend to enlarge design spaces, sometimes by more than an order of magnitude. Unfortunately, disturbances, noise, and uncertainties will prevent real processes from ever reaching "steady state". Therefore, design spaces calculated at steady state cannot be used to guarantee quality specifications. In fact, because design spaces fail to take into account any process dynamics, constraining a controller to work within a design space may result in failure to meet quality specifications, significant degradation of controller performance, and input jitter. As a substitute for design space, robust model predictive control (RMPC) is a promising technology for dynamically guaranteeing constraint satisfaction on process outputs. Although many RMPC algorithms have been proposed in the literature, the computational cost of these algorithms tends to be a strong function of the state vector size. This is problematic for continuous pharmaceutical processes, which are typically high- or infinite-dimensional. However, input-output models (e.g. finite step response models) can integrated with traditional RMPC strategies to robustly control high-dimensional systems. Although RMPC can be used to counteract the presence of disturbances, uncertainty, and measurement noise, faults also present a threat to quality constraint satisfaction of continuous pharmaceutical processes. Active fault diagnosis of hybrid systems is particularly difficult due to the explosion of mode combinations with prediction horizon. Fortunately, the set of input sequences which do not guarantee diagnosis can be outer bounded offline as a function of a parameterized initial condition set. This enables an algorithm for guaranteed active fault diagnosis of hybrid systems which can be implemented quickly online.
by Lucas Charles Foguth.
Ph. D.
Pauli, Victoria [Verfasser]. "Development and Implementation of a Redundant Process Control Strategy in Pharmaceutical Continuous Manufacturing / Victoria Pauli." Düsseldorf : Universitäts- und Landesbibliothek der Heinrich-Heine-Universität Düsseldorf, 2019. http://d-nb.info/1195213417/34.
Повний текст джерелаCollins, Donovan (Donovan Scott). "Feature-based investment cost estimation based on modular design of a continuous pharmaceutical manufacturing system." Thesis, Massachusetts Institute of Technology, 2011. http://hdl.handle.net/1721.1/66063.
Повний текст джерела"June 2011." Cataloged from PDF version of thesis.
Includes bibliographical references (p. 72-73).
Previous studies of continuous manufacturing processes have used equipment-factored cost estimation methods to predict savings in initial plant investment costs. In order to challenge and validate the existing methods of cost estimation, feature-based cost estimates were constructed based on a modular process design model. Synthesis of an existing chemical intermediate was selected as the model continuous process. A continuous process was designed that was a literal, step by step, translation of the batch process. Supporting design work included process flow diagrams and basic piping and instrumentation diagrams. Design parameters from the process model were combined with feature-based costs to develop a series of segmented cost estimates for the model continuous plant at several production scales. Based on this analysis, the continuous facility seems to be intrinsically less expensive only at a relatively high production scale. Additionally, the distribution of cost areas for the continuous facility differs significantly from the distribution previous assumed for batch plants. This finding suggests that current models may not be appropriate for generating cost estimates for continuous plants. These results should not have a significant negative impact on the value proposition for the continuous manufacturing platform. The continuous process designed for this project was not optimized. Therefore, this work reiterates that the switch to continuous must be accompanied with optimization and innovation in the underlying continuous chemistry.
by Donovan Collins.
S.M.
M.B.A.
Holman, James William. "Assessing the use of twin screw wet granulation in a multi stage manufacturing process for the continuous production of pharmaceutical products." Thesis, University of Surrey, 2013. http://epubs.surrey.ac.uk/807047/.
Повний текст джерелаWilburn, Kristopher Ray. "The business case for continuous manufacturing of pharmaceuticals." Thesis, Massachusetts Institute of Technology, 2010. http://hdl.handle.net/1721.1/59190.
Повний текст джерелаCataloged from PDF version of thesis.
Includes bibliographical references (p. 52-53).
Manufacturing in the pharmaceutical industry is presently characterized as a batch production system, which has existed in its current form for decades. This structure is the result of historical regulatory policy as well as the conservative nature of the industry. Recent clarification by US and European regulatory bodies has opened the possibility to new approaches to the manufacturing process. This combined with changes in the market for the pharmaceutical industry has accelerated the rate at which new manufacturing technologies are explored. Continuous manufacturing is a paradigm shift in the pharmaceutical industry manufacturing structure, encompassing several new technologies and systems. The business impact of continuous manufacturing has not been well defined. This assessment aims to compare a continuous manufacturing process to a batch manufacturing process for a particular Novartis product. The product has an established batch production process. Cost estimates and the continuous process cost is estimated using a four-step process: defining the process flow, performing the material balance, estimating the capital costs, and estimating the operating costs. This analysis shows that for the particular Novartis product considered, a continuous process is an improvement over the batch process in four performance characteristics: capital investment, operating cost, throughput time, and working capital requirement.
by Kristopher Ray Wilburn.
S.M.
M.B.A.
Книги з теми "Continuous pharmaceutical manufacturing"
Subramanian, Ganapathy, ed. Continuous Processing in Pharmaceutical Manufacturing. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2014. http://dx.doi.org/10.1002/9783527673681.
Повний текст джерелаAlper, Joe, ed. Continuous Manufacturing for the Modernization of Pharmaceutical Production. Washington, D.C.: National Academies Press, 2019. http://dx.doi.org/10.17226/25340.
Повний текст джерелаKhinast, Johannes, and Jukka Rantanen. Continuous Manufacturing of Pharmaceuticals. Edited by Peter Kleinebudde. Chichester, UK: John Wiley & Sons, Ltd, 2017. http://dx.doi.org/10.1002/9781119001348.
Повний текст джерелаKleinebudde, Peter, Johannes Khinast, and Jukka Rantanen. Continuous Manufacturing of Pharmaceuticals. Wiley & Sons, Incorporated, John, 2017.
Знайти повний текст джерелаKleinebudde, Peter, Johannes Khinast, and Jukka Rantanen. Continuous Manufacturing of Pharmaceuticals. Wiley & Sons, Incorporated, John, 2017.
Знайти повний текст джерелаDouroumis, Dionysios, Peter Kleinebudde, Johannes Khinast, Jukka Rantanen, and Martin J. Snowden. Continuous Manufacturing of Pharmaceuticals. Wiley & Sons, Limited, John, 2017.
Знайти повний текст джерелаKleinebudde, Peter, Johannes Khinast, and Jukka Rantanen. Continuous Manufacturing of Pharmaceuticals. Wiley & Sons, Limited, John, 2017.
Знайти повний текст джерелаSubramanian, Ganapathy. Continuous Processing in Pharmaceutical Manufacturing. Wiley-VCH Verlag GmbH, 2014.
Знайти повний текст джерелаSubramanian, Ganapathy. Continuous Processing in Pharmaceutical Manufacturing. Wiley & Sons, Incorporated, John, 2014.
Знайти повний текст джерелаSubramanian, Ganapathy. Continuous Processing in Pharmaceutical Manufacturing. Wiley & Sons, Limited, John, 2014.
Знайти повний текст джерелаЧастини книг з теми "Continuous pharmaceutical manufacturing"
Johnson, Martin D., Scott A. May, Michael E. Kopach, Jennifer Mc Clary Groh, Timothy Donald White, Kevin P. Cole, Timothy Braden, Luke P. Webster, and Vaidyaraman Shankarraman. "Continuous Reactors for Pharmaceutical Manufacturing." In Continuous Pharmaceutical Processing, 23–50. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-41524-2_2.
Повний текст джерелаGanesh, Sudarshan, and Gintaras V. Reklaitis. "Basic Principles of Continuous Manufacturing." In Continuous Pharmaceutical Processing, 1–21. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-41524-2_1.
Повний текст джерелаMorefield, Elaine. "Regulatory Considerations for Continuous Manufacturing." In Continuous Pharmaceutical Processing, 513–35. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-41524-2_15.
Повний текст джерелаSu, Qinglin, Gintaras V. Reklaitis, and Zoltan K. Nagy. "Continuous Feeding-Blending in Pharmaceutical Continuous Manufacturing." In Continuous Pharmaceutical Processing, 193–226. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-41524-2_6.
Повний текст джерелаGiridhar, Arun, and Gintaras V. Reklaitis. "Real-Time Optimization: How to Change Setpoints in Pharmaceutical Manufacturing." In Continuous Pharmaceutical Processing, 429–40. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-41524-2_12.
Повний текст джерелаJohnson, Martin D., Scott A. May, Jennifer McClary Groh, Timothy Braden, and Richard D. Spencer. "Intermittent Flow and Practical Considerations for Continuous Drug Substance Manufacturing." In Continuous Pharmaceutical Processing, 87–127. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-41524-2_4.
Повний текст джерелаSu, Qinglin, Sudarshan Ganesh, Gintaras V. Reklaitis, and Zoltan K. Nagy. "Active Process Control in Pharmaceutical Continuous Manufacturing – The Quality by Control (QbC) Paradigm." In Continuous Pharmaceutical Processing, 395–427. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-41524-2_11.
Повний текст джерелаSrai, Jagjit Singh, Ettore Settanni, and Parminder Kaur Aulakh. "Evaluating the Business Case for Continuous Manufacturing of Pharmaceuticals: A Supply Network Perspective." In Continuous Pharmaceutical Processing, 477–512. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-41524-2_14.
Повний текст джерелаSteiner, Richard, and Maik Jornitz. "Continuous Processing in the Pharmaceutical Industry: Status and Perspective." In Continuous Manufacturing of Pharmaceuticals, 369–403. Chichester, UK: John Wiley & Sons, Ltd, 2017. http://dx.doi.org/10.1002/9781119001348.ch11.
Повний текст джерелаBorukhova, Svetlana, and Volker Hessel. "Continuous Manufacturing of Active Pharmaceutical Ingredients via Flow Technology." In Continuous Manufacturing of Pharmaceuticals, 127–67. Chichester, UK: John Wiley & Sons, Ltd, 2017. http://dx.doi.org/10.1002/9781119001348.ch4.
Повний текст джерелаТези доповідей конференцій з теми "Continuous pharmaceutical manufacturing"
Schenkendorf, Rene. "Supporting the shift towards continuous pharmaceutical manufacturing by condition monitoring." In 2016 Conference on Control and Fault-Tolerant Systems (SysTol). IEEE, 2016. http://dx.doi.org/10.1109/systol.2016.7739813.
Повний текст джерелаOhtake, S., A. Langford, and B. Luy. "Current needs of the pharmaceutical industry: opportunities and challenges for implementing novel drying technologies." In 21st International Drying Symposium. Valencia: Universitat Politècnica València, 2018. http://dx.doi.org/10.4995/ids2018.2018.8354.
Повний текст джерелаNikolakopoulou, Anastasia, Matthias von Andrian, and Richard D. Braatz. "Plantwide Control of a Compact Modular Reconfigurable System for Continuous- Flow Pharmaceutical Manufacturing." In 2019 American Control Conference (ACC). IEEE, 2019. http://dx.doi.org/10.23919/acc.2019.8814781.
Повний текст джерелаElkhashap, Ahmed, Robin Meier, and Dirk Abel. "A Grey Box Distributed Parameter Model for a Continuous Vibrated Fluidized Bed Dryer in Pharmaceutical Manufacturing." In 2020 European Control Conference (ECC). IEEE, 2020. http://dx.doi.org/10.23919/ecc51009.2020.9143770.
Повний текст джерелаNikolakopoulou, Anastasia, Matthias von Andrian, and Richard D. Braatz. "Fast Model Predictive Control of Startup of a Compact Modular Reconfigurable System for Continuous-Flow Pharmaceutical Manufacturing." In 2020 American Control Conference (ACC). IEEE, 2020. http://dx.doi.org/10.23919/acc45564.2020.9147331.
Повний текст джерелаScholl, Stephan. "From Batch to Continuous Production Through Micro Process Technology: Chances and Challenges." In ASME 2008 6th International Conference on Nanochannels, Microchannels, and Minichannels. ASMEDC, 2008. http://dx.doi.org/10.1115/icnmm2008-62028.
Повний текст джерелаNelson, Cartwright, Slesha Tuladhar, and Md Ahasan Habib. "Designing an Interchangeable Multi-Material Nozzle System for 3D Bioprinting Process." In ASME 2021 16th International Manufacturing Science and Engineering Conference. American Society of Mechanical Engineers, 2021. http://dx.doi.org/10.1115/msec2021-63471.
Повний текст джерелаSchoenitz, Martin, Annika Hohlen, Wolfgang Augustin, and Stephan Scholl. "In-Process Cleaning of a Micro Heat Exchanger With Ultrasound During the Continuous Crystallization of Solid Lipid Nanoparticles." In ASME 2014 12th International Conference on Nanochannels, Microchannels, and Minichannels collocated with the ASME 2014 4th Joint US-European Fluids Engineering Division Summer Meeting. American Society of Mechanical Engineers, 2014. http://dx.doi.org/10.1115/icnmm2014-21821.
Повний текст джерелаMustafa, Khalid, and Kai Cheng. "Managing Complexity in Manufacturing Changeovers: A Sustainable Manufacturing-Oriented Approach and the Application Case Study." In ASME 2016 11th International Manufacturing Science and Engineering Conference. American Society of Mechanical Engineers, 2016. http://dx.doi.org/10.1115/msec2016-8744.
Повний текст джерелаFritsch, Klaus. "GWP® - The Science-Based Global Standard for Efficient Lifecycle Management of Weighing Systems." In NCSL International Workshop & Symposium. NCSL International, 2012. http://dx.doi.org/10.51843/wsproceedings.2012.22.
Повний текст джерелаЗвіти організацій з теми "Continuous pharmaceutical manufacturing"
Agu, Monica, Zita Ekeocha, Stephen Robert Byrn, and Kari L. Clase. The Impact of Mentoring as a GMP Capability Building Tool in The Pharmaceutical Manufacturing Industry in Nigeria. Purdue University, December 2012. http://dx.doi.org/10.5703/1288284317447.
Повний текст джерела